Jr. David R. Holmes's research while affiliated with Mayo Clinic - Rochester and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (3)
Background: Ten-year all-cause death according to incomplete (IR) versus complete revascularization (CR) has not been fully investigated in patients with three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) undergoing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG).
Methods: The SYNTAX E...
Citations
... Hajjo et al. proposed an approach that carefully weighs the benefts and risks of immunosuppression in COVID-19 vaccine-induced myocarditis, suggesting the selective use of corticosteroids, particularly glucocorticoids, for a limited duration in patients with acutely impaired left ventricular function [126][127][128]. Additionally, aspirin, intravenous immunoglobulin, betablockers, and angiotensin-converting enzyme inhibitors may be considered for patients with left ventricular systolic dysfunction [129,130]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/274772483375104-1442522273898_Q64/Enrico-Ammirati.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/279426140000261-1443631791274_Q64/Eric-Adler-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281083095421-1662401640524_Q64/Leslie-Cooper-2.jpg)
... 18 The analysis of Synergy between PCI with Taxus and Cardiac Surgery extended survival study revealed no significant difference in 10-year mortality between CR and ICR in the CABG arm. 19 It is contrary to the recent meta-analysis of 28 studies with a median follow-up of 4.7 years that reported greater survival benefit in CR compared with ICR. 20 Further analyses suggested that the benefit of CR is especially apparent in high-risk patients. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/553604001918977-1509000887414_Q64/Patrick-Serruys.jpg)
